Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2022  |  Volume : 35  |  Issue : 2  |  Page : 559-566

The Value of serum Golgi protein 73 as a biomarker for hepatocellular carcinoma


1 Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Menoufia University, Shebin Elkom, Egypt
2 Department of Hepatology, National Liver Institute, Menoufia University, Shebin Elkom, Egypt

Correspondence Address:
Hasnaa M Shibl
Department of Medical Biochemistry and Molecular Biology, Menoufia University, Shebin Elkom, 32511
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/mmj.mmj_225_21

Rights and Permissions

Background Hepatocellular carcinoma (HCC) is the most common liver cancer arising from the hepatocytes. The most prevalent noninvasive biological marker for diagnosis of HCC is alpha-fetoprotein (AFP). Golgi protein 73 (GP73) was considered as an impending biological marker for the early diagnosis of HCC. Objectives To assess the value of GP73 in serum as a biological marker for HCC comparing its sensitivity and specificity with serum AFP. Methods This study included 90 participants (30 patients with hepatitis-C virus (HCV)-related HCC, 30 patients having liver cirrhosis on top of chronic HCV, and 30 healthy controls). The levels of AFP and GP73 in serum were measured by chemiluminescent immune-metric assay and enzyme-linked immunosorbent assay techniques, respectively. Results HCC and cirrhotic patients had considerably higher AFP (P < 0.001, <0.004) and GP73 (P < 0.001, 0.047) levels than controls, whereas HCC patients had significant higher values of AFP and GP73 than cirrhotic patients (P = 0.029, <0.001, respectively). Combined AFP + GP73 had the highest sensitivity and specificity (P < 0.001) for differentiating HCC patients from controls. In discrimination of HCC patients from cirrhotic patients, serum GP73 had the highest sensitivity and specificity (P < 0.001) than AFP (P = 0.009) and combined AFP + GP73 (P < 0.001). Moreover, in discrimination of metastatic patients from nonmetastatic ones, combined AFP + GP73 had the highest sensitivity (P < 0.001) than GP73 alone (P = 0.013), whereas AFP alone had the highest specificity (P = 0.058) than combined AFP + GP73. Conclusion GP73 is a reliable biological marker for early diagnosis and detection of distant metastasis of cancerous liver diseases in patients having liver cirrhosis on top of chronic HCV infection and it would yield better results when used combined with AFP.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed594    
    Printed24    
    Emailed0    
    PDF Downloaded77    
    Comments [Add]    

Recommend this journal